ANI Pharmaceuticals (NASDAQ:ANIP) Rating Lowered to Hold at BidaskClub

Share on StockTwits

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, BidAskClub reports.

ANIP has been the topic of a number of other reports. ValuEngine raised Xylem from a “hold” rating to a “buy” rating in a report on Friday, June 21st. Canaccord Genuity downgraded Magellan Aerospace from a “buy” rating to a “hold” rating and reduced their price target for the company from C$21.00 to C$20.00 in a research note on Monday, May 13th. Zacks Investment Research downgraded ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Raymond James restated a “buy” rating on shares of Canadian Natural Resources in a research note on Friday, May 10th. Finally, TheStreet upgraded TerraForm Power from a “c” rating to a “b-” rating in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $84.50.

ANIP stock opened at $81.36 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67. The firm has a market cap of $962.23 million, a price-to-earnings ratio of 17.07 and a beta of 2.25. ANI Pharmaceuticals has a 1-year low of $36.92 and a 1-year high of $84.10. The business’s 50 day simple moving average is $75.21.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.25. The business had revenue of $52.90 million for the quarter, compared to analyst estimates of $50.57 million. ANI Pharmaceuticals had a return on equity of 28.63% and a net margin of 6.58%. The firm’s revenue was up 13.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.32 EPS. As a group, research analysts predict that ANI Pharmaceuticals will post 5.57 EPS for the current fiscal year.

In other news, insider Arthur Przybyl sold 30,000 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $70.07, for a total transaction of $2,102,100.00. Following the completion of the sale, the insider now directly owns 222,994 shares in the company, valued at approximately $15,625,189.58. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director David Nash bought 1,445 shares of the business’s stock in a transaction dated Friday, May 24th. The shares were bought at an average price of $68.76 per share, with a total value of $99,358.20. Following the completion of the transaction, the director now owns 5,236 shares in the company, valued at approximately $360,027.36. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 50,911 shares of company stock valued at $3,585,114. Corporate insiders own 24.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. WINTON GROUP Ltd boosted its position in shares of ANI Pharmaceuticals by 80.5% during the 2nd quarter. WINTON GROUP Ltd now owns 7,868 shares of the specialty pharmaceutical company’s stock valued at $647,000 after purchasing an additional 3,509 shares in the last quarter. First Trust Advisors LP boosted its holdings in ANI Pharmaceuticals by 1.2% in the first quarter. First Trust Advisors LP now owns 15,122 shares of the specialty pharmaceutical company’s stock worth $1,067,000 after acquiring an additional 179 shares in the last quarter. Marshall Wace LLP bought a new position in ANI Pharmaceuticals in the first quarter worth approximately $797,000. Phocas Financial Corp. boosted its holdings in ANI Pharmaceuticals by 8.9% in the first quarter. Phocas Financial Corp. now owns 140,977 shares of the specialty pharmaceutical company’s stock worth $9,945,000 after acquiring an additional 11,501 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new position in ANI Pharmaceuticals in the first quarter worth approximately $626,000. Hedge funds and other institutional investors own 63.92% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Read More: Purposes and Functions of the Federal Reserve

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.